Recent Updates
Recently added Catalysts
DMAC Positive Sentiment

DiaMedica Therapeutics to Report Third Quarter 2026 Financial Results and Provide a Business Update November 13, 2026

Thursday, November 5, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: DiaMedica Therapeutics will release its third quarter 2026 financial results on November 12th, after market close. A live conference call is scheduled for November 13th at 8:00 AM ET to discuss the results and provide a business update. The company focuses on treatments for preeclampsia, fetal growth restriction, and acute ischemic stroke.

Market Sentiment Analysis

POSITIVE FACTORS

  • DiaMedica is focusing on critical conditions like preeclampsia.
  • The company is preparing to report its financial results.
  • A live conference call will provide a business update.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~13 mo
Low dilution risk
Lead asset
DM199
Phase 3 · Acute Stroke

Full Press Release Details

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke (AIS), today announced that its third quarter 2026 financial results will be released after the markets close on Thursday, November 12th. DiaMedica will host a live conference call on Friday, November 13th at 8:00 AM Eastern Time / 7:00 AM Central Time to provide a business

Frequently Asked Questions

When will DiaMedica report its Q3 2026 results?

DiaMedica will report its Q3 2026 results on November 12, 2026.

What time is the conference call for the results?

The conference call is scheduled for November 13 at 8:00 AM ET.

What conditions does DiaMedica focus on?

DiaMedica focuses on preeclampsia, fetal growth restriction, and AIS.

Where will the financial results be released?

The financial results will be released after market close.

ShareAdd on Google
Tags: DMAC DiaMedica financial results preeclampsia acute ischemic stroke fetal growth restriction
Last updated: Nov 5, 2026

Biotech snapshot

Cash runway
$44M liquidity · $3M/mo burn
~13 mo
Low dilution risk
Lead asset
DM199Phase 3
Acute Stroke →